PCI Biotech Holding Logo

PCI Biotech Holding

Biopharma firm evaluating its future after discontinuing its core technology development.

PCIB | OL

Overview

Corporate Details

ISIN(s):
NO0010405640
LEI:
5967007LIEEXZXFIGG77
Country:
Norway
Address:
Ullernchausséen 64, 0379 OSLO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PCI Biotech Holding is a biopharmaceutical company that was focused on developing a proprietary photochemical technology platform. This platform was designed to enhance intracellular drug delivery for therapeutic applications, including immunotherapy and dermatology, and to advance the bioprocessing and manufacturing of viral vectors for gene therapy. In August 2025, the company announced the discontinuation of its core technology development. Consequently, PCI Biotech is currently evaluating its future operations and strategic direction.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 15:36
Business and Financial Review
PCI Biotech update on future operations
English 3.6 KB
2025-08-26 16:14
Report Publication Announcement
PCI Biotech: Invitation to first half 2025 results presentation and corporate u…
English 2.3 KB
2025-08-22 14:15
Major Shareholding Notification
Flaggemelding
Norwegian 411 bytes
2025-08-22 11:09
Major Shareholding Notification
Flaggemelding
Norwegian 451 bytes
2025-08-18 20:39
Regulatory News Service
PCI Biotech announces discontinuation of development of the PCL technology and …
English 3.4 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
Norwegian 449.8 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
English 866 bytes
2025-05-20 20:08
Declaration of Voting Results & Voting Rights Announcements
PCI BIotech: Disclosure of voting rights for Chair of the Board
English 1.2 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 188.6 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 146.9 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 167.8 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 208.0 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 977 bytes
2025-04-24 15:30
Annual Report (ESEF)
PCI Biotech Holding ASA: Annual Report 2024
English 5.4 MB
2025-04-24 15:30
Annual Report
PCI Biotech Holding ASA: Annual Report 2024
English 1.2 MB

Automate Your Workflow. Get a real-time feed of all PCI Biotech Holding filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PCI Biotech Holding via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
NATURECELL CO.,LTD. Logo
Biotech company developing stem cell therapies, food, beverages, and cosmetics.
South Korea 007390
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893

Talk to a Data Expert

Have a question? We'll get back to you promptly.